|
⚲
|
| Keyboard |
| Paladin Capital Management LLC
✚
|
|
|---|---|
| CRD # | 122679 |
| SEC # | 801-61489 |
| CIK # | 0001788497 |
| AUM | 1,300.2 M (2026-06-10) |
| Employees | 24 (71% Investors, 0% Brokers) |
| Phone | 202-293-5590 |
| Address | 2000 K Street NW Washington, DC 20006 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Paladin Cyber Fund III Cayman Islands LP | 2025-03-28 | 74.6 M | |
| PE | Paladin Cyber Fund III LP | 2025-03-28 | 47.0 M | |
| PE | Paladin Digital Biology Co-Invest Fund LLC | 2024-03-26 | 1.1 M | |
| PE | Paladin Digital Biology Fund Cayman Islands LP | 2024-03-26 | 11.4 M | |
| PE | Paladin Digital Biology Fund LP | [2024-03-26] | 14.6 M | 2.2 M |
| Filed 2023-09-06 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Paladin Cyber Fund II A LP | 2023-03-29 | 58.7 M | |
| PE | E Street Investments LLC | 2022-03-30 | 69.9 M | |
| PE | Paladin Cyber Fund II Cayman Islands LP | 2022-03-30 | 126.6 M | |
| PE | Paladin Cyber Co-Invest Fund II LLC | 2021-03-29 | 51.6 M | |
| PE | Paladin Cyber Fund II Jersey LP | 2021-03-29 | 89.6 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 26 | 1,300.2 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 26 | 1,300.2 |
| By Discretionary | ||
| Discretionary | 26 | 1,300.2 |
| Non-Discretionary | 0 | 0.0 |
| Total | 26 | 1,300.2 |
| By Non-United States Persons | ||
| Non-United States Persons | 734.0 | |
| United States Persons | 566.1 | |
| Total | 26 | 1,300.2 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Michael Steed | Executive Officer | 4 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001788497] | |
| 4 | [0001788497] | |
| SC 13G | [0001788497] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Paladin Capital Management LLC | 10X Genomics Inc | [2020-02-18] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.6B |
| Serves | Institutional |
| Fund Types | Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
10x Genomics Inc TXG
Class A Common Stock
|
2020-04-30 | Sell | 1,000,000 | $78.25 | 78,250,000 |
|
10x Genomics Inc TXG
Class A Common Stock
|
2020-04-21 | Sell | 568 | $74.48 | 42,305 |
|
10x Genomics Inc TXG
Class A Common Stock
|
2020-03-17 | Other | 1,527,241 | $0.00 | |
|
10x Genomics Inc TXG
Class A Common Stock
|
2020-03-16 | Other | 619,306 | $0.00 | |
|
10x Genomics Inc TXG
Class A Common Stock
|
2020-02-20 | Conversion | 8,675,167 | ||
|
10x Genomics Inc TXG
Class B Common Stock · derivative
|
2020-02-20 | Conversion | 8,675,167 | ||
|
10x Genomics Inc TXG
Series A-1 Convertible Preferred Stock · derivative
|
2019-09-16 | Conversion | 790,487 | $0.00 | |
|
10x Genomics Inc TXG
Series D Convertible Preferred Stock · derivative
|
2019-09-16 | Conversion | 653,082 | $0.00 | |
|
10x Genomics Inc TXG
Class B Common Stock · derivative
|
2019-09-16 | Conversion | 790,487 | $0.00 | |
|
10x Genomics Inc TXG
Series B Convertible Preferred Stock · derivative
|
2019-09-16 | Conversion | 2,476,963 | $0.00 | |
|
10x Genomics Inc TXG
Series A-2 Convertible Preferred Stock · derivative
|
2019-09-16 | Conversion | 3,749,767 | $0.00 | |
|
10x Genomics Inc TXG
Class B Common Stock · derivative
|
2019-09-16 | Conversion | 1,004,868 | $0.00 | |
|
10x Genomics Inc TXG
Series C Convertible Preferred Stock · derivative
|
2019-09-16 | Conversion | 1,004,868 | $0.00 | |
|
10x Genomics Inc TXG
Class B Common Stock · derivative
|
2019-09-16 | Conversion | 2,476,963 | $0.00 | |
|
10x Genomics Inc TXG
Class B Common Stock · derivative
|
2019-09-16 | Conversion | 653,082 | $0.00 | |
|
10x Genomics Inc TXG
Class B Common Stock · derivative
|
2019-09-16 | Conversion | 3,749,767 | $0.00 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Newlight Partners LP
✚
|
NY | 1,324.7 M |
|
North Castle Partners LLC
✚
|
NY | 1,321.1 M |
|
OTRO Capital Management LLC
✚
|
NY | 1,315.9 M |
|
Northampton Capital Partners LLC
✚
|
FL | 1,309.5 M |
|
Sagewind Capital LLC
✚
|
NY | 1,297.1 M |
|
Advantage Capital Investment Adviser LLC
✚
|
LA | 1,294.7 M |
|
BIP Capital LLC
✚
|
GA | 1,290.7 M |
|
Rizvi Traverse Management LLC
✚
|
FL | 1,285.4 M |
|
TTCP Management Services LLC
✚
|
MN | 1,284.9 M |
|
Redefine Ventures LLC
✚
|
CO | 1,283.2 M |